Aurobindo Pharma completes acquisition of US-based Lannett Company

Listed Co AcquisitionStrategic Transactions View source PDF Explain this filing

AUROPHARMA · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

+2.3%Reaction day

₹1538.30

prior close

₹1576.60

announcement price

In-mkt

timing

Nifty Midcap 150market+0.4%+1.9% vs market

Pharmaceuticals peers, median of 165sector+0.8%+1.5% vs sector

On the reaction day the stock moved 1.9 pts more than Nifty Midcap 150 and 1.5 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

+0.1

10m

-0.1

15m

-0.2

30m

-0.4

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

+2.3+0.4+1.9+0.8+1.5

Next day

+0.8+0.6+0.1+0.3+0.5

+1.6+1.1+0.5+0.8+0.8

+5.1+0.9+4.2+1.2+3.9

+3.6+1.3+2.4+0.6+3.0

+2.9+1.0+1.9+0.1+2.8

+2.9+0.8+2.1+0.6+2.3

15d

+3.0+2.2+0.8+1.7+1.2

+2.5+1.6+1.0-0.5+3.0

+11.6+3.8+7.8+2.7+8.9

+8.7-3.6+12.3+3.2+5.5

UpDownMarket · Nifty Midcap 150Sector · Pharmaceuticals peers, median of 165Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Aurobindo Pharma's wholly owned US subsidiary APUSA has completed the acquisition of Lannett Company Inc. from Lannett Seller Holdco, effective June 29, 2026. The deal received US FTC approval on June 18, 2026. Lannett now becomes a wholly owned subsidiary of APUSA and will operate as Lannett Company LLC. Over 400 Lannett employees will join APUSA, and integration begins immediately.

Likely market impact

Strengthens Aurobindo's US generics footprint; adds Lannett's product portfolio, manufacturing capacity, and about 400 employees.